表紙
市場調查報告書

中國的Sorafenib市場分析

Investigation Report on Chinese Sorafenib Market, 2018-2022

出版商 China Research and Intelligence 商品編碼 335239
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Sorafenib市場分析 Investigation Report on Chinese Sorafenib Market, 2018-2022
出版日期: 2018年07月11日內容資訊: 英文 30 Pages
簡介

本報告提供中國的Sorafenib市場相關調查分析,銷售額,價格,主要製造商分析,市場預測等系統性資訊。

第1章 Sorafenib的基本概念

  • 適應
  • 中國的Sorafenib的發展歷史
  • 中國的Sorafenib的登記資訊

第2章 中國的Sorafenib的銷售額

  • 中國的Sorafenib的整體銷售額
  • 中國的Sorafenib的銷售額:各地區
  • Sorafenib的銷售額:各劑型

第3章 中國的Sorafenib主要製造商分析

  • Bayer
  • 印度的企業
  • 中國製學名藥的發展

第4章 中國的Sorafenib的價格

  • Bayer
  • 印度走私的學名藥

第5章 中國的Sorafenib市場預測

  • 市場規模的預測
  • 競爭格局的預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1807304

Sorafenib is mainly used to treat inoperable advanced renal cell carcinoma and inoperable or metastasized primary hepatocellular carcinoma. Sorafenib was jointly developed by Bayer and ONYX. In 2006, the drug was approved to be imported to China. In 2008, it entered China after the liver cancer indication was approved by the CFDA.

Liver cancer is the sixth most common cancer in the world and the second leading cause of cancer-related death. It is estimated that over 800 thousand cases of liver cancer are diagnosed worldwide (more than 400 thousand cases in China) every year with a continuous increase in incidence. In 2012, around 746 thousand people died of liver cancer, including 383 thousand deaths in China. As the most effective targeted drug for liver cancer, Sorafenib brings hope to numerous tumor patients.

According to CRI, Sorafenib has been growing since it entered China. In 2017, its sales value in China was about CNY 195 million. Currently, Sorafenib legally sold in China are all Bayer's products.

According to CRI, cancer incidence continues to rise in China because of aggravating environmental pollution and changing lifestyle. Therefore, there will be a great demand for Sorafenib. After several links of circulation, Bayer's Sorafenib is so high-priced that many low-income patients cannot afford it. Some patients choose to purchase Sorafenib produced by Indian enterprises such as NATCO and smuggled to China because the price is only 2%-3% of that of Bayer's Sorafenib. Some Chinese enterprises has also started the development of generic drugs.

It is possible that China-made Sorafenib will appear on the market after 2022.

Topics Covered:

  • Sales of Sorafenib in China
  • Prices of Sorafenib in China
  • Sales of Sorafenib in China by region
  • Sales of India-made Sorafenib in China
  • Prospects of Chinese Sorafenib market

Table of Contents

1 Basic Concepts of Sorafenib

  • 1.1 Indications
  • 1.2 Development History of Sorafenib in China
  • 1.3 Registration Information of Sorafenib in China

2 Sales of Sorafenib in China, 2013-2017

  • 2.1 Overall Sales of Sorafenib in China
    • 2.1.1 Sales Value
    • 2.1.2 Sales Volume
  • 2.2 Sales of Sorafenib in China by Region
    • 2.2.1 Sales Value by Region
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Sorafenib by Dosage Form

3 Analysis on Major Sorafenib Manufacturers in China

  • 3.1 Bayer
  • 3.2 Indian Enterprises
  • 3.3 Progress of China-made Generic Drugs

4 Prices of Sorafenib in China, 2017-2018

  • 4.1 Bayer (Product Trade Name: NATCO)
  • 4.2 Generic Drugs Smuggled from India

5 Prospects of Chinese Sorafenib Market, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Competition Pattern

Selected Charts

  • Chart Governmental Approval of Sorafenib in China
  • Chart Sales Value of Sorafenib Legally Sold in China, 2013-2017
  • Chart Sales Value of Sorafenib in Parts of China, 2013-2017
  • Chart Sales Volume of Sorafenib in China, 2013- 2017
  • Chart Sales Volume of Sorafenib in Parts of China, 2013-2017
  • Chart Market Share of Sorafenib Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Sorafenib Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value and Market Share of Sorafenib Tablets in China, 2013-2017
  • Chart Sales Volume and Market Share of Sorafenib Tablets in China, 2013-2017
  • Chart Prices of Bayer's Sorafenib in Several Chinese Cities, 2017-2018
Back to Top